CUFF GUARD MODELLO INFANT

Informazioni principali

  • Nome commerciale:
  • CUFF GUARD MODELLO INFANT
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Dispositivo medico

Documenti

  • per il pubblico:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per il pubblico.

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • CUFF GUARD MODELLO INFANT
    Italia
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • CUFFIE COPRISTRUMENTI E APPARECCHI

Altre informazioni

Status

  • Fonte:
  • Ministero della Salute - Italia
  • Stato dell'autorizzazione:
  • S
  • Data dell'autorizzazione:
  • 23-03-2010
  • Ultimo aggiornamento:
  • 09-08-2016
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.

    Richiedi il foglio illustrativo per il pubblico.

15-1-2019

Expanded recall: Shermag recalls Harrison convertible 4 in 1 crib

Expanded recall: Shermag recalls Harrison convertible 4 in 1 crib

The hardware on the cribs can become loose and detach, allowing the sides of the crib to widen, creating a hazardous gap in which infants and toddlers can become wedged or entrapped, posing risks of suffocation and strangulation.Hardware failures can also lead to the crib to collapse as sides may detach.

Health Canada

7-12-2018

Strawberry-flavoured acetaminophen infant oral drops in 24 mL bottles recalled because of defective child-resistant safety caps

Strawberry-flavoured acetaminophen infant oral drops in 24 mL bottles recalled because of defective child-resistant safety caps

Laboratoire RivaInc. and Laboratoires Trianon Inc. are voluntarily recalling five over-the-counter strawberry-flavoured acetaminophen oral drops for infants. The products are labeled as Biomedic, Option, Personnelle, Selection, or Laboratoires Trianon Inc. The products are packaged in 24 mL bottles and are used for pain and fever relief. They are being recalled because the child-resistant safety cap may be defective. This recall is in addition to previous recalls of children’s acetaminophen syrups for th...

Health Canada

6-12-2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level. The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen.

FDA - U.S. Food and Drug Administration

29-11-2018

ANSES and CEA join forces to strengthen technological innovation in order to safeguard health

ANSES and CEA join forces to strengthen technological innovation in order to safeguard health

During the symposium organised to mark the sixtieth anniversary of the creation of the ANSES Laboratory in Ploufragan (Côtes d'Armor), on Thursday 29 November 2018, Roger Genet, Director General of ANSES, and Stéphane Siebert, Director of Technological Research at the CEA, signed a framework partnership agreement aimed at strengthening their cooperation to develop innovative technological tools in order to improve responsiveness in the fields of animal and plant health and food safety.

France - Agence Nationale du Médicament Vétérinaire

28-11-2018

ANSES provides access to the data from its study on dietary exposure of children under three years of age to chemicals

ANSES provides access to the data from its study on dietary exposure of children under three years of age to chemicals

ANSES is publishing all the data from its Infant Total Diet Study (iTDS). Available as OpenData on the official website data.gouv.fr, this document presents all the data on concentrations of chemical residues or contaminants in the diet of children under three years of age. "Total Diet Studies" (TDS) are national surveys that aim to estimate people's exposure to chemical contaminants in food. They rely on the analysis of a large number of substances in food samples that reflect consumption by the popula...

France - Agence Nationale du Médicament Vétérinaire

25-10-2018

i play., inc. recalls Flower Rattle

i play., inc. recalls Flower Rattle

Pieces of the rattle can detach, posing a choking hazard to infants.

Health Canada

16-10-2018

Abond Group Inc. recalls Tubeez Baby Bath Support

Abond Group Inc. recalls Tubeez Baby Bath Support

The bath support’s suction cups may not adhere to the bath surface, making it unstable and cause it to possibly tip over while in use. In addition, an infant can slip underneath the front support bar and become lodged under water posing a drowning hazard.

Health Canada

19-9-2018

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

Published on: Tue, 18 Sep 2018 00:00:00 +0200 During the years 2012‐2016, the Dutch National Food Consumption survey was conducted in the Netherlands. For the survey, a random sample was drawn from consumer panels stratified by age and gender and maintained representative to the population with regard to region, address density and educational level. Complete results were obtained for 4,313 persons (response rate 65%); including toddlers, children, adolescents, adults and elderly. Pregnant or lactating ...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Livestock Health and Food Chain Risk Assessment

Livestock Health and Food Chain Risk Assessment

Published on: Mon, 27 Aug 2018 00:00:00 +0200 The EUFORA fellowship programme ‘Livestock Health and Food Chain Risk Assessment’ was proposed by the Animal and Plant Health Agency (APHA), a British governmental institution responsible for safeguarding animal and plant health in the UK. The working programme, which was organised into four different modules, covered a wide range of aspects related to risk assessment including identification of emerging risks, risk prioritisation methods, scanning surveilla...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Update of the tolerable upper intake level for vitamin D for infants

Update of the tolerable upper intake level for vitamin D for infants

Published on: Tue, 07 Aug 2018 00:00:00 +0200 The European Food Safety Authority (EFSA) carried out a public consultation to receive input from the scientific community and all interested parties on the draft Scientific Opinion on the update of the tolerable upper intake level for vitamin D for infants. This draft Scientific Opinion was prepared by the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA Panel) and endorsed by the Panel for public consultation by written procedure on 9 April 20...

Europe - EFSA - European Food Safety Authority Publications

22-8-2018

King Bio Issues Voluntary Nationwide Recall of It’s Kids and Infant Products Due to Potential Microbial Contamination

King Bio Issues Voluntary Nationwide Recall of It’s Kids and Infant Products Due to Potential Microbial Contamination

King Bio is voluntarily recalling the below products to the consumer level. A small percentage of our products produced between 08/01/2017 and 04/2018 have tested positive for microbial contamination. Out of an abundance of caution, we are recalling the products and lot numbers below

FDA - U.S. Food and Drug Administration

30-7-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on efforts to safeguard women’s health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for “vaginal rejuvenation”

Statement from FDA Commissioner Scott Gottlieb, M.D., on efforts to safeguard women’s health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for “vaginal rejuvenation”

FDA warns doctors and patients about deceptive claims on laser medical devices used to treat menopausal symptoms for “vaginal rejuvenation”

FDA - U.S. Food and Drug Administration

19-7-2018

Food additive re-evaluation: EFSA workshop in November focuses on foods for infants below 16 weeks of age

Food additive re-evaluation: EFSA workshop in November focuses on foods for infants below 16 weeks of age

Food additive re-evaluation: EFSA workshop in November focuses on foods for infants below 16 weeks of age

Europe - EFSA - European Food Safety Authority Press Releases & News Stories

16-7-2018

Determinazioni AIFA (16/07/2018)

Determinazioni AIFA (16/07/2018)

L'Agenzia Italiana del Farmaco rende disponibili un elenco di Determine riguardanti la classificazione ai sensi dell'art. 12 comma 5 legge 8 novembre 2012 n. 189 di medicinali per uso umano - approvati con procedura centralizzata.

Italia - AIFA - Agenzia Italiana del Farmaco

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

11-6-2018

Peekaboo Beans Inc. recalls Peekaboo Beans Dark Heather Charcoal Infant Garments

Peekaboo Beans Inc. recalls Peekaboo Beans Dark Heather Charcoal Infant Garments

The bean logo can become detached, posing a potential choking hazard.

Health Canada

24-5-2018

Three questions for Gilles Salvat, ANSES Managing Director General for Research and Reference

Three questions for Gilles Salvat, ANSES Managing Director General for Research and Reference

As Reference Delegation Day is held at ANSES, bringing together representatives of national and European reference laboratories, Gilles Salvat, Managing Director General for Research and Reference, gives us an overview of this essential part of ANSES's work. What do you mean by reference? Reference is an essential component of the system for safeguarding health. The work of the reference laboratories is vital to improving knowledge and identification of the major hazards we face in food safety, animal...

France - Agence Nationale du Médicament Vétérinaire

23-5-2018

FDA takes action against the use of OTC benzocaine teething products due to serious safety risk, lack of benefit

FDA takes action against the use of OTC benzocaine teething products due to serious safety risk, lack of benefit

OTC oral health products containing benzocaine for the temporary relief of sore gums due to teething in infants or children should no longer be marketed. FDA is asking companies to stop selling these products for such use and requesting that companies add new warnings to all other benzocaine oral health products to describe certain serious risks.

FDA - U.S. Food and Drug Administration

23-5-2018

Oral Over-the-Counter Benzocaine Products: Drug Safety Communication  - Risk of Serious and Potentially Fatal Blood Disorder

Oral Over-the-Counter Benzocaine Products: Drug Safety Communication - Risk of Serious and Potentially Fatal Blood Disorder

Oral over-the-counter benzocaine products should not be used to treat infants and children younger than 2 years and should only be used in adults and children 2 years and older if they contain certain warnings on the drug label.

FDA - U.S. Food and Drug Administration

22-5-2018

Determinazioni AIFA (22/05/2018)

Determinazioni AIFA (22/05/2018)

L'Agenzia Italiana del Farmaco rende disponibili un elenco di Determine riguardanti la classificazione ai sensi dell'art. 12 comma 5 legge 8 novembre 2012 n. 189 di medicinali per uso umano - approvati con procedura centralizzata.

Italia - AIFA - Agenzia Italiana del Farmaco

26-4-2018

Nota Informativa Importante su azitromicina (02/05/2018)

Nota Informativa Importante su azitromicina (02/05/2018)

L'Agenzia Italiana del Farmaco rende disponibili nuove e importanti informazioni riguardo l'aumento del tasso di recidive delle neoplasie ematopoietiche e della mortalità nei pazienti sottoposti a trapianto di cellule staminali ematopoietiche (HSCT) che assumono azitromicina.

Italia - AIFA - Agenzia Italiana del Farmaco

20-12-2018

The use of necklaces, bracelets,& other jewelry marketed for relieving teething pain can lead to serious injuries or death & should not be used to reduce teething pain in infants or to provide sensory  stimulation to persons with special needs. Learn more

The use of necklaces, bracelets,& other jewelry marketed for relieving teething pain can lead to serious injuries or death & should not be used to reduce teething pain in infants or to provide sensory stimulation to persons with special needs. Learn more

The use of necklaces, bracelets,& other jewelry marketed for relieving teething pain can lead to serious injuries or death & should not be used to reduce teething pain in infants or to provide sensory stimulation to persons with special needs. Learn more: https://go.usa.gov/xEaWn  pic.twitter.com/RScrgBUSYj

FDA - U.S. Food and Drug Administration

19-12-2018

On 12/12/18 GE Healthcare Recalled CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA has identified this as a Class I Recall, the most serious type recall. Read more about the recall:  https://go.usa.gov/

On 12/12/18 GE Healthcare Recalled CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA has identified this as a Class I Recall, the most serious type recall. Read more about the recall: https://go.usa.gov/

On 12/12/18 GE Healthcare Recalled CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA has identified this as a Class I Recall, the most serious type recall. Read more about the recall: https://go.usa.gov/xE383  #MedicalDevice #FDA pic.twitter.com/S2EbMdmwpe

FDA - U.S. Food and Drug Administration

14-12-2018

GE Healthcare Recalls CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA @US has identified this as a Class I Recall, the most serious type recall. Read more about the recall here:  https://go.usa.gov/xE38

GE Healthcare Recalls CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA @US has identified this as a Class I Recall, the most serious type recall. Read more about the recall here: https://go.usa.gov/xE38

GE Healthcare Recalls CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA @US has identified this as a Class I Recall, the most serious type recall. Read more about the recall here: https://go.usa.gov/xE383  #MedicalDevice #FDA pic.twitter.com/X4IprwU8R2

FDA - U.S. Food and Drug Administration

26-11-2018


Withdrawn application: HopGuard Gold, purified semi-solid extract from Humulus lupulus L. containing approximately 48% of beta acids as potassium salts, Date of withdrawal: 12/04/2018, Initial authorisation

Withdrawn application: HopGuard Gold, purified semi-solid extract from Humulus lupulus L. containing approximately 48% of beta acids as potassium salts, Date of withdrawal: 12/04/2018, Initial authorisation

Withdrawn application: HopGuard Gold, purified semi-solid extract from Humulus lupulus L. containing approximately 48% of beta acids as potassium salts, Date of withdrawal: 12/04/2018, Initial authorisation

Europe - EMA - European Medicines Agency

7-8-2018

LETIFEND (Laboratorios LETI, S.L.unipersonal)

LETIFEND (Laboratorios LETI, S.L.unipersonal)

LETIFEND (Active substance: Recombinant Protein Q from L. infantum MON-1) - Centralised - Yearly update - Commission Decision (2018)5415 of Tue, 07 Aug 2018

Europe -DG Health and Food Safety

28-6-2018

Procedimento di definizione del budget e del ripiano per l’anno 2017 (28/06/2018)

Procedimento di definizione del budget e del ripiano per l’anno 2017 (28/06/2018)

Si fa seguito alle comunicazioni del 25 maggio e del 14 giugno, e si conferma che per quanto riguarda i dati dell’anno 2017, tramite il Portale del monitoraggio e del controllo della spesa farmaceutica, AIFA  ha messo  a disposizione (https://www.agenziafarmaco.gov.it/aifarsf/login) per ciascun codice SIS i seguenti dati, aggiornati al 27-06-2018 a seguito del processo di verifica avviato il 25/05/2018.

Italia - AIFA - Agenzia Italiana del Farmaco

19-6-2018

Nota Informativa Importante su Tecentriq (atezolizumab) (09/07/2018)

Nota Informativa Importante su Tecentriq (atezolizumab) (09/07/2018)

L'Agenzia Italiana del Farmaco rende disponibili nuove e importanti informazioni su Tecentriq (atezolizumab) riguardo una restrizione dell’indicazione terapeutica per il trattamento del carcinoma uroteliale localmente avanzato o metastatico in pazienti adulti non eleggibili al trattamento con chemioterapia contenente cisplatino.

Italia - AIFA - Agenzia Italiana del Farmaco

25-5-2018

Avvio del procedimento di definizione del budget e del ripiano per l’anno 2017 (25/05/2018)

Avvio del procedimento di definizione del budget e del ripiano per l’anno 2017 (25/05/2018)

Si comunica che, in ottica di un confronto costruttivo con tutti gli stakeholders della filiera del farmaco (industria e distribuzione del farmaco), per quanto riguarda i dati dell’anno 2017, tramite il Portale del monitoraggio e del controllo della spesa farmaceutica, AIFA ha messo a disposizione (https://www.agenziafarmaco.gov.it/aifarsf/login), per ciascun codice SIS, dati aggiornati al 25/05/2018.

Italia - AIFA - Agenzia Italiana del Farmaco